Welcome to SWEBAGS
The Swedish Basal Ganglia Society, SWEBAGS, is an non-profit scientific organization providing a platform for discussions and education opportunities in the area of basal ganglia research.
We aim to increase the visibility of mainly basic and pre-clinical research, and foster multidisciplinary collaborations across biological scales and methodological approaches. All professionals, students and organisations interested in basal ganglia research are welcome to become members.
Together we will leverage the strengths of basal ganglia research in Sweden, join us in our efforts and participate in our activities!
– Jeanette Hellgren Kotaleski, Professor, KTH Royal Institute of technology, Chair SWEBAGS
– Angela Cenci Nilsson, Professor, Lund University, Vice Chair SWEBAGS
Latest News:
Open position as Assistant Professor and Group Leader at Lund University (Lund, Sweden)
Area: Neurodegenerative disease research, with focus on disease mechanisms. Faculty affiliation: Medical Faculty 5-years position with the opportunity for promotion to permanent employment as a senior lecturer. The salary is covered by Lund University Several forms of support will be provided by the strategic research area MultiPark (multidisciplinary research on neurogenerative diseases, https://www.multipark.lu.se) How to apply Applications are…
Postdoc opportunity in the Trudeau lab in Montreal to study dopamine neuron biology and vulnerability
Exploring the fundamental mechanisms of dopamine release and dopamine neuronvulnerabilitySupervisor: Dr. Louis-Eric Trudeau A postdoc position is presently available in the laboratory of Dr. Louis-Eric Trudeau at theUniversity of Montreal to work on projects that focus on the fundamental mechanisms ofdopamine release and on the vulnerability of these neurons in Parkinson’s disease models.The ideal applicant…
New Publication: Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia
Authors: Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastian A. Barrientos, Pär Halje, Azat Nasretdinov, Luciano Censoni, Sebastian Sulis Sato Evgenya Malinina, Joakim Tedroff, Nicholas Waters, Per Petersson Abstract: Levodopa provides effective symptomatic treatment for Parkinson’s disease. However, nonmotor symptoms are often insufficiently relieved, and its long-term use is complicated by motor fluctuations and dyskinesia. To clarify…
